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Inadequate immunomodulatory potency of mesenchymal stem cells (MSC) may limit their
therapeutic efficacy. We report glucocorticoid steroids augment MSC expression and activity of
indoleamine-2,3-dioxygenase (IDO), a primary mediator of MSC immunomodulatory function. This effect
depends on signaling through the glucocorticoid receptor and is mediated through up-regulation of
FOXO3. Treatment of MSCs with glucocorticoids, budesonide or dexamethasone, enhanced IDO
expression following IFN-c stimulation in multiple donors and was able to restore IDO expression in
over-passaged MSCs. As IDO enhancement was most notable when cells were continuously exposed to
budesonide, we engineeredMSCwith budesonide loaded PLGAmicroparticles.MSC efficiently internalized
budesonide microparticles and exhibited 4-fold enhanced IDO activity compared to budesonide
preconditioned and naı¨ve MSC, resulting in a 2-fold improvement in suppression of stimulated peripheral
bloodmononuclear cells in an IDO-dependent manner. Thus, the augmentation of MSC immunemodulation
may abrogate challenges associated with inadequate potency and enhance their therapeutic efficacy.
T
he potential of mesenchymal stem cells (MSCs) to ameliorate inflammation arising from numerous diseases
has been established in preclinical animal models leading to hundreds of MSC clinical trials1,48. While MSCs
appear to be beneficial in several disease models, treatment of patients has led to highly variable outcomes.
For example, subsets of patients with graft versus host disease (GvHD) have responded remarkably well to MSC
therapy with at least temporary resolution of symptoms2,3, while for others their prognosis is unaltered4,5. Factors
limiting MSC therapy include insufficient and variable immunomodulatory potency6–8, dependence on in vivo
activation by host inflammatory mediators to achieve MSC immunomodulation7–9, and limited MSC persist-
ence10,11. Substantial batch to batch variability in MSC secretome8, in vitro immunomodulatory potential1,6,7, and
treatment efficacy linked to differences in MSC donors2,3,6,7, tissue of origin4–6,12, and passages2,6–8 have recently
been reported. Furthermore, limited persistence shortens the therapeutic window in which MSCs modulate
inflammatory responses via secretion of growth factors and cytokines, release of exosomes, or activity of immu-
nomodulatory enzymes such as iNOS and IDO. Thus, techniques to augment and control the potency ofMSC are
needed for a therapeutic effect to be exerted within a short therapeutic window.We hypothesize that engineering
MSCs to maximize and sustain immunosuppressive potential will enable the generation of enhanced cell-based
therapies and eliminate the need to contemplate from which tissue or donor MSCs should be derived.
One of the primary factors mediating MSC immune suppression is the tryptophan depleting enzyme indo-
leamine-2,3-dioxygenase (IDO). Inhibiting IDO with 1-methyl-DL-tryptophan (1-MT) in human MSCs abro-
gates their immunosuppressive potential in peripheral blood mononuclear cell (PBMC) co-cultures7–9,13. In
contrast to secreted factors implicated in MSC immune suppression such as PGE210,11,14 or TSG-68,10, IDO is
an intracellular enzyme. Specifically, IDO is the first and rate-limiting enzyme involved in degradation of
tryptophan down the kynurenine pathway and is predominately expressed in antigen presenting cells (APCs)
in response to type I interfons15. Additionally, human MSCs have been shown to have IDO-dependent anti-
microbial affects against staphylococcus aureus, staphylococcus epidermis, and toxoplasma gondii16. As in APCs,
expression of IDO in MSCs occurs in response to inflammation, induced by exposure to interferon-c (IFN-c).
Both the depletion of tryptophan and the generation of kynurenine byproducts have potent suppressive effects on
immune cells15,17. IDO has been implicated in promoting both physiological and pathological tolerance. IDO
expressed by cells in the placenta is responsible for fetal tolerance, and inhibition of IDO by the inhibitor
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1-methyl-tryptophan (1-MT) results in allograft rejection of the
fetus18. More recently, IDO has been found to be overexpressed in
solid tumors, promoting tolerance towards tumor antigens19 and
tryptophan depletion has been shown to suppress T-cell proliferation
through activation of general control non-depressing 2 (GCN2)
kinase20. In addition to tryptophan depletion, IDO generates trypto-
phan catabolites that inhibit the proliferation of activated T-cells21
and induce naı¨ve T-cells to become FoxP31T-regulatory cells22. Due
to the role of IDO as a negative regulator of inflammation and indu-
cer of tolerance, the level and regulation of its expression is of great
interest for maternal-fetal tolerance, tumor immunity, allergy, auto-
immune disease, transplant tolerance, and MSC therapy. Unfor-
tunately, the level of MSC IDO expression varies significantly
between donors and between MSC tissue sources leading to variabil-
ity in MSC’s ability to suppress activated T-cells6,7.
As elevated IDO activity correlates with enhanced suppression of
T-cell activation and proliferation, augmenting MSC IDO levels
should increase their immunomodulatory potency. Interestingly,
IDO expression in macrophages and dendritic cells has been shown
to be augmented by exposure to glucocorticoid steroids mediated in
part through cell-cell contact signaling through interactions between
the glucocorticoid-induced tumor necrosis factor receptor related
protein (GITR) and its ligand (GITRL)23,24. Similarly, augmented
IDO expression following glucocorticoid steroid treatment has also
been observed in astrocytes, although the mechanism of steroid
enhanced IDO activity is not known25. While MSCs are frequently
administered to patients with GvHD who are already receiving
glucocorticoid steroids3,26, the impact of glucocorticoid steroids
on MSCs, and specifically on their IDO activity, has not been
investigated.
Herein, we report that budesonide, a glucocorticoid steroid with
fewer systemic effects than dexamethasone27, significantly boosts
MSC IDO activity and immunosuppressive phenotype and we intro-
duce a cell engineering strategy to sustain MSC therapeutic potency
without requiring soluble budesonide. Specifically, we observe that
budesonide-treated MSCs show similar metabolic activity, viability,
and morphology to untreated MSCs, yet exhibit a favorable shift in
their expression of immunogenic and immunosuppressive factors. In
addition to enhancing IFN-c induced IDO expression and activity,
BUD treatment also significantly reduced MSC expression of MHC
molecules. We found that combined exposure to both budesonide
and inflammatory cues resulted in the highest levels of IDO express-
ion, as IDO is only expressed in response to inflammatory signaling.
Additionally, the response was broadly applicable to other glucocor-
ticoids, as dexamethasone produced a similar IDO response, and
blocking the glucocorticoid receptor inhibited the enhanced IDO
expression. To engineer cells with enhanced and sustained immu-
nosuppressive potency that can be activated upon entering an
inflammatory environment without requiring systemic administra-
tion of immunosuppressant drugs, we utilized a particle engineering
approach. Budesonide loaded microparticles were efficiently inter-
nalized by MSCs and resulted in significant enhancement of MSC
IDO expression and activity, similar to soluble budesonide. In vitro
co-culture assays with PBMCs revealed the engineered MSCs could
be activated in situ in response to IFN-c produced by PBMCs.
Engineered MSC suppression of PBMCs was enhanced further by
pre-activating MSCs with IFN-c to increase expression of IDO prior
to the initiation of the PBMC co-cultures. Addition of the IDO
inhibitor 1-MT completely abolished the suppressive properties of
the engineered MSCs, implicating IDO as a key immunosuppressive
factor.We believe this engineering strategy could be used to augment
MSC potency, resulting in enhanced cell-based therapies.
Results
Impact of budesonide on MSC viability and morphology. Gluco-
corticoid steroids are commonly prescribed anti-inflammatory drugs
that have diverse effects on immune cells, however their effect on
MSC immunogenicity and immunomodulatory potential has not
been thoroughly examined. Glucocorticoid steroids exert their
effects through binding cytoplasmic glucocorticoid receptors and
translocating to the nucleus where they bind glucocorticoid respon-
ive elements (GREs), resulting in promotion or suppression of gene
expression28. As such, glucocorticoid steroids, such as budesonide,
have variable effects on cells of different origins, including growth
inhibition29, suppression of MHC expression28,30, and induction of
IDO25.
To examine if budesonide alters MSC potency without negatively
impacting MSC phenotype, MSCs were exposed to 0.001–100 mM
budesonide for 24–72 hours. Metabolic activity, as assessed by XTT,
was not significantly affected by budesonide treatment for 24, 48, or
72 hours over the dosage range tested (Fig. 1A). Flow cytometry
analysis revealed no significant changes in MSC viability as evi-
denced by dual negative staining for Annexin-V and propidium
iodide after 72 hours of budesonide exposure (Fig. 1B). Phase con-
trast imaging of treated cells did not show any appreciable impact of
budesonide on the morphology of MSCs after 48 hours of budeso-
nide exposure (Fig. 1C). In addition, MSCs treated with budesonide
for 48 hours showed no evidence of increased cell death when eval-
uated for double stranded DNAbreaks by TUNEL staining (Fig. 1D).
Collectively these data show MSC metabolic activity, morphology,
proliferation, and viability were preserved over a wide range of bude-
sonide concentrations.
Impact of budesonide on MSC immunophenotype. Next we
analyzed the effect of budesonide on MSC expression of MHC I
and MHC II molecules. The naturally low expression of MHC I,
lack of MHC II, and failure of MSC to elicit hyperacute rejection
upon infusion has been used to justify the use of unmatched
allogeneic MSCs in animal models and clinical trials. However,
upon exposure to an inflammatory environment, expression of
both MHC molecules increases31. Interestingly, glucocorticoids
have been shown to reduce expression of MHC molecules in many
cell types28,30. Expression of class I and class IIMHCmolecules, HLA-
ABC and HLA-DR respectively, were examined to investigate
budesonide’s impact on MSC immunophenotype before and after
IFN-c stimulation. MSCs were exposed to vehicle (DMSO) or
budesonide for 24 hours after which media was changed to include
IFN-c and the cells were cultured for an additional 48 hours prior to
antibody staining and flow cytometry analysis. Cells in the ‘drug
preconditioning’ group were exposed to budesonide only during
the first 24 hours while cells in the ‘drug sustained’ group were
exposed to budesonide for the duration of the experiment
(Fig. 2A). Figure 2B shows that MSC expression of HLA-ABC was
reduced by over 50% for all doses of budesonide in both the
precondition and drug sustained groups (p , 0.001). Following
exposure to 100 mM budesonide, stimulation with IFN-c reduced
HLA-ABC expression by only ,15% (not significant (NS), Fig. 2B,
C). Budesonide treatment did not result in any increase of HLA-DR
expression in unstimulated conditions or decrease in HLA-DR in
stimulated conditions except for the 100 mM treated group.
Preconditioning with 100 mM budesonide reduced IFN-c induced
HLA-DR expression by 11% (NS) while sustained exposure resulted
in a 40% reduction (p , 0.001, Fig. 2D,E).
Impact of budesonide on MSC IDO activity. MSC immunosup-
pressive potential was evaluated following exposure to budesonide
through assessment of IDO protein content and activity. Following
treatment of MSCs with 1 mM budesonide for 24 hours, MSCs were
additionally exposed to 100 ng/ml IFN-c for 48 hours (Fig. 3A).
MSCs were collected, lysed, and IDO protein content was analyzed
by western blot. Budesonide treatment alone did not result in any
increase in IDO protein content over untreatedMSCs (Fig. 3B). IFN-
c stimulation resulted in increased IDO content in both untreated
www.nature.com/scientificreports
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and budesonide treated MSCs, with budesonide treated cells
containing significantly more IDO than untreated controls. To
determine the extent to which budesonide could enhance MSC
IDO expression, IDO content of MSCs from multiple donors and
passages was analyzed with and without budesonide treatment.
Enhancement in IDO expression following budesonide exposure
was observed in MSCs from multiple donors, regardless of the
baseline level of IDO expression (no budesonide treatment) for
each donor (Fig. 3C). In addition, high passage, P8, MSCs treated
with budesonide expressed IDO at levels greater or similar to
untreated P5 MSCs (Fig. 3D). Interestingly, IDO expression was
most significantly enhanced when budesonide was continuously
present versus simply pretreated (Fig. 3E,F). To demonstrate the
ability to enhance the immunomodulatory potency of MSCs with
poor immunosuppressive potential, donor #7083, which had the
lowest baseline IFN-c inducible IDO expression (no budesonide
Figure 1 | Viability, metabolic activity, and morphology of budesonide treated MSC (A) MSC were plated in 96 well plates (15,000 cells/well)
treated with DMSO or 0.001–100 uM budesonide and their metabolic activity was assessed by XTT at 24, 48, and 72 hours.K cell condition (7,500 cells/
well) used as control to show a reduction in XTT signal when fewer cells are present. (B)MSCswere plated in 24 well plates (30,000 cells/well) treated with
DMSO or 0.001–100 uM budesonide. At 24, 48, and 72 hours after plating, cells were harvested, and viability was measured by staining with Annexin V
and propidium iodide and analyzing by flow cytometry. Staurosporine (STS) treatment for 1 and 3 hour was used as a positive control for cell death.
(C) Representative phase contrast images of MSCs treated with budesonide for 48 hours show no change in morphology, density, or adherence.
(D) TUNEL staining for double stranded DNA breaks after 48 hour budesonide exposure shows no increase in apoptosis. Stain control cells were treated
with DNase to induce DNA breaks and served as a positive control for TUNEL stain. (DAPI, Blue; TUNEL, Green). (Bars are mean 6 SEM, 2-way
ANOVA with Fishers LSD test, n 5 3, *p , 0.05) Scale bar 100 mm.
www.nature.com/scientificreports
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treatment) of the three donors, was used for all subsequent experi-
ments. As the immunomodulatory function of IDO is dependent on
its activity as an enzyme, an enzymatic activity assay was performed.
Specifically, MSCs were grown according to the protocol depicted in
Fig. 3A, collected, lysed to isolate IDO from the cytoplasm, and the
quantity of L-kynurenine produced was measured by a colorimetric
assay. Exposure to budesonide had a dramatic effect on MSC’s IDO
activity. While IDO expression naturally increases upon stimulation
with IFN-c, additional conditioning by budesonide resulted in an
over 4-fold increase in IDO activity (Fig. 3G).
Mechanism of IDO augmentation. To begin to elucidate the
mechanism of budesonide-mediated enhancement of MSC IDO
expression, we examined the timing and activation of intracellular
pathways likely to be involved. Elevated IDO levels were first de-
tected by western blot 24 hours after IFN-c exposure (Fig. 4A,B),
consistent with previous reports that show IFN-c stimulates new
transcription of IDO mRNA in MSCs6. Furthermore, the effect
does not appear to be mediated through increased sensitivity to
IFN-c, as the timing and degree of Stat-1 phosphorylation between
untreated (Fig. 4A) and budesonide treated (Fig. 4B) MSCs were
Figure 2 | Impact of budesonide on relativeMHCmolecule expression (A) Timing ofMSC exposure to budesonide and IFN-c in the Drug Precondition
and Drug Sustained groups. Flow cytometric analysis of (B,C) HLA-ABC and (D,E) HLA-DR surface expression of MSCs. MSC were plated in 25 cm2
flasks (100,000 MSC/flask) with media containing vehicle or budesonide and were either stimulated with IFN-c or left unstimulated. MSC were then
cultured an additional 48 hours without budesonide (Drug Precondition) or with budesonide (Drug Sustained). (B,D) show mean fluorescence
intensity (MFI) for each condition. (Bars are mean 6 SEM, One-way ANOVA with Bonferroni correction for multiple comparisons, n 5 3, *p, 0.001
compared to untreated control). (C,E) show representative flow cytometry plots including isotype controls.
www.nature.com/scientificreports
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nearly identical. In addition, the pattern of immediate increase in
phosphorylated Stat-1 following IFN- c exposure and an increase in
total Stat-1 following 24 hours of IFN- c treatment is consistent with
patterns described in the literature for human cell lines32–34. Next we
examined if budesonide was exerting its effect on IDO expression
through the glucocorticoid receptor. Blocking the glucocorticoid
receptor with 2 mM of RU486 reversed budesonide’s enhancing
effect on IDO expression back to baseline levels (Fig. 4C). This
data suggests budesonide mediated enhancement of IDO is
dependent on the glucocorticoid receptor. Consistent with this
observation is the finding that treatment with either budesonide or
dexamethasone, both glucocorticoid steroids, results in similar
enhancement in IDO expression (Fig. 4D). Interestingly, the pro-
moter region for the IDO gene does not contain any known gluco-
corticoid responsive elements (GRE). Thus, steroid enhancement of
IDO is likely mediated through up-regulation of a glucocorticoid
responsive intermediary that enhances the transcription of IDO.
Therefore we looked for transcription factors known to bind the
IDO promoter that are also sensitive to glucocorticoid steroids.
IDO has previously been reported to be promoted by FOXO317, a
transcription factor which has recently been shown to be a target of
the glucocorticoid receptor35. To determine FOXO3’s role in
budesonide-mediated enhancement of MSC IDO, we performed
siRNA knockdown experiments. MSCs were transfected with
FOXO3 siRNA or scramble siRNA as a control and then treated
with budesonide for 24 hours, after which cells were treated with
IFN-c. FOXO3 expression was measured 6 hours after IFN-c
addition (preliminary experiments revealed peak FOXO3 content
at this time point) and IDO was measured 30 hours after IFN-c
addition. Transfection of MSCs with FOXO3 siRNA resulted in
Figure 3 | IDO expression ismaximized following IFN-c and budesonide exposure. (A) Timing ofMSC exposure to budesonide and IFN-c. (B)Western
blot of IDOprotein contentmeasured fromMSC exposed to 1 mMbudesonide and 100 ng/ml IFN-c. b-actin shown as loading control. (C)Western blot
of IDO protein content measured from MSCs harvested from three independent donors exposed to 1 mM budesonide and 100 ng/ml IFN-c. b-actin
shown as loading control. (D) P5 and P8 MSCs were treated with vehicle or budesonide for 24 hours and then additionally with 100 ng/ml IFN-c for
48 hours. Cell lysate was collected and analyzed for IDO content by western blot. (E) Impact of IFN-c and budesonide on the enzymatic activity of IDO
harvested fromMSC (donor 7083) lysate measured by production of kynurenine. 5 mg/ml rhIDOwas used as an internal control for the assay(right axis).
(Bars are mean 6 SEM One-way ANOVA with Tukey correction for multiple comparisons, n 5 3, *p , 0.001). (F) Timing of MSC exposure to
budesonide and IFN-c. IFN-c was applied immediately following budesonide treatment or following a 24 hour delay in the preconditioning groups.
(G) Western blot of IDO protein content measured from MSCs exposed to [V] DMSO vehicle, or [P] preconditioned, or [C] continuously exposed to
1 mM budesonide. A 0 or 24 hour delay was introduced between the 24 hour budesonide preconditioning and exposure to IFN-c. b-actin shown as
loading control.
www.nature.com/scientificreports
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nearly complete inhibition of FOXO3 (Fig. 4E) and reverted
budesonide treated MSC IDO expression (Fig. 4F) and activity
(Fig. 4G) back to the level of untreated MSCs. Collectively this
data suggests budesonide’s effect on MSC IDO expression is
mediated by glucocorticoid-induced expression of FOXO3 which
then acts as a genomic enhancer to augment IDO expression.
Establishing prolonged control of MSCs. We next sought to exa-
mine if we could prolong enhanced MSC IDO activity without the
need for continuous exposure to soluble budesonide. Glucocorticoid
steroids are commonly used clinically and potentially could be co-
administered with MSCs, however, their lack of specificity causes
them to have numerous off-target effects that can be detrimental
to the overall health of a patient27,36,37. Thus, developing a method
to control MSC phenotype without requiring co-administration of
systemic glucocorticoid steroids thereby minimizing systemic
exposure is desirable. To achieve prolonged control of MSC IDO
activity we drew from our prior experience loading MSCs with
drug loaded poly(lactic-co-glycolic acid) (PLGA) microparticles38.
Previously we have shown that using the particle-in-cell approach,
1 mm particles can be efficiently internalized into MSCs and remain
stable for at least 7-days during which time, small molecule drugs can
be released to influence the phenotype of cells38–40.
Budesonide microparticles ,1 mm in diameter with low polydis-
persity were formulated to control MSC IDO activity (Fig. 5A,B).
Surface modification of the particles with poly-L-Lysine resulted in a
Figure 4 | Budesonide enhancement of IDO occurs through glucocorticoid receptor mediated upregulation of FOXO3 and not increased sensitivity to
IFN-c.MSCs were treated with (A) vehicle only or (B) 1 mM budesonide for 24 hours and then additionally exposed to 100 ng/ml IFN-c (continuous
exposure to vehicle or budesonide). Lysates of (A) untreated (vehicle only)MSCs and (B) 1 mMbudesonide treatedMSCs were collected at 0, 1, 6, 12, and
24 hours after IFN-c exposure. To determine the timing of IDO up-regulation IDO protein content was measured at each time point. To determine if
budesonide enhanced MSC sensitivity to IFN-c, the degree of Stat-1 phosphorylation was measured as stat-1 phosphorylation is classically induced by
IFN-c stimulation. b-actin shown as loading control. (bottom) Ratio of pStat-1 to total Stat-1 is shown for each time point. (C) Inhibition of the
glucocorticoid receptor with RU486 reverts IDO levels back to baseline levels in budesonide treated MSCs. (D) Western blot of IDO protein content
measured from IFN-c stimulated MSC exposed to DMSO vehicle, budesonide, or dexamethasone. b-actin shown as loading control. To test the
dependence of enhanced IDO expression on FOXO3, siRNAknockdownwas performed.MSCswere transfectedwith FOXO3 siRNAor scrambled siRNA
for 5 hours and then treated with budesonide for 24 hours followed by IFN-c treatment. Cell lysates were collected 6 and 30 hours following addition of
IFN-c and analyzed for (E) FOXO3 and (F) IDO respectively. To confirm that inhibition of FOXO3prevents enhanced expression of IDO, an IDOactivity
assay was performed. (G) Activity of IDO harvested from lysates of vehicle, budesonide, budesonide/FOXO3 siRNA, and budesonide/scrambled siRNA
treated MSCs 48 hours after IFN-c stimulation. (Bars are mean 6 SEM, One-way ANOVA with Tukey correction for multiple comparisons, n 5 3,
*p , 0.01).
www.nature.com/scientificreports
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zeta potential of110 mV (Fig. 5B), which we have previously shown
enhances particle uptake39. Budesonide was extracted from the part-
icles and the drug loading (7.05%, Fig. 5B) and encapsulation effi-
ciency (51.2%, Fig. 5B) were determined byHPLC. 10 kDamolecular
weight PLGA was used to formulate the particles to ensure rapid
release of the drug during the first week following MSC particle
modification. Release kinetic experiments were performed, revealing
a burst release of 20% of total drug in the first 12 hours followed by a
continuous release, with ,80% of total drug released by day 10
(Fig. 5C). MSC internalization of particles was optimized as prev-
iously described39 by modulating the size and zeta-potential of the
particles. MSC association with 1 mm PLGA particles coated with
poly-L-Lysine was confirmed by flow cytometry showing nearly all
MSCs associated with particles (Fig. 5D). Confocal imaging revealed
PLGA particles were not merely associating with the outer plasma
membrane, but internalized (Fig. 5E). MSC’s were engineered with
BUD-Particles without impacting cell viability (Fig. 5F).
To test if the intracellular release of budesonide from PLGA part-
icles would work similarly to soluble budesonide, we examined the
expression and activity of IDO within cell lysates. MSCs were modi-
fied with either BUD-PLGA or Blank-PLGA particles overnight,
allowed to rest 24 hours, and then stimulated with IFN-c for
48 hours, after which cells were harvested for analysis (Fig. 6A). As
with soluble budesonide, BUD-PLGA particle modification signifi-
cantly increased the content of IDO in MSC lysate (Fig. 6B). In
addition, when compared head to head, BUD-PLGA particle modi-
fied MSCs expressed higher levels of IDO than MSCs simply pre-
treated with soluble budesonide before IFN-c activation (Fig. 6C).
Finally, BUD-PLGAmodifiedMSCs exhibited a 53 augmentation in
IDO enzymatic activity over Blank-PLGAmodified and unmodified
MSCs (Fig. 6D), an effect similar to what was observed with soluble
budesonide (Fig. 3G).
Enhanced immunosuppressive properties in vitro. To test our
hypothesis that enhanced IDO activity would lead to enhanced
immunosuppression, MSCs were co-cultured with CD3/CD28
Dynabead activated PBMCs. BUD-Particle modified MSCs showed
significantly enhanced suppression over budesonide preconditioned
MSCs, which showed no advantage over naı¨ve MSCs (Fig. 6E). To
determine the degree of BUD-Particle modified MSC enhancement
over naı¨ve MSCs, ratiometric MSC:PBMC co-cultures were
established by fixing the number of PBMCs in each well and
varying the number of MSCs plated to achieve MSC:PBMC ratios
of 154, 158, or 1516. Unmodified, Blank-Particle modified, and
BUD-Particle modified MSCs each suppressed PBMC proliferation
in a cell-dose dependent manner. However, BUD-Particle MSCs
showed enhanced suppression of PBMCs at all ratios tested as
evidenced by reduced proliferation (Fig. 7C,D) and decreased IFN-
c production (Fig. 7E). Impressively, BUD-Particle MSC co-cultures
at 158 and 1516 ratios were as effective at suppressing PBMC
proliferation and IFN-c secretion as native MSCs at 154 and 158
ratios, respectively. In other words, twice as many unmodified MSCs
are required to achieve an equivalent in vitro suppressive effect as
BUD-Particle MSCs.
As IDO activity is dependent on IFN-c stimulation, we hypothe-
sized the effect could be further accentuated by pre-activation of
MSCs. Activating MSCs with IFN-c prior to the co-culture enhances
IDO expression of theMSCs tomaximize potency at the beginning of
the assay. This is akin to activatingMSCs prior to administration to a
patient to maximize potency without relying on the recipient for
Figure 5 | Budesonide particle modification to enable sustained control of MSC phenotype. (A) Fluorescent image of DiI labeled Budesonide PLGA
microparticles(Scale bar 5 mm). (B) Physicochemical properties of budesonide PLGA microparticles. (C) Release kinetics of budesonide from 2 mg of
PLGA microparticles into PBS at 37uC. (D) MSC association with 1 mm, PLL coated particles was assessed by flow cytometry (Representative plot).
(E) Representative confocal image of an MSC modified with 1 mm diameter PLGA particles (white arrows point to red particles) revealing particles are
predominately intracellular rather than membrane associated (membrane stained Green, nuclei shown in Blue, scale bar 10 mm). (F) Particle modified
MSC viability examined by TUNEL staining. TUNEL stain shown in green with nuclei counterstained with Hoechst (Blue). (bottom) Percent apoptotic
cells (mean 6 SD, TUNEL1/Hoechst 1 nuclei, n 5 3) shown in each image (Scale bar 50 mm).
www.nature.com/scientificreports
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activation. Thus, the MSC:PBMC co-cultures were repeated with
MSCs preconditioned with IFN-c for 48 hours to stimulate IDO
expression prior to plating in the co-cultures. Pre-activation of
MSC IDO expression resulted in similar trends in unmodified
MSCs, inferior suppression by Blank-Particle MSCs, and further
enhanced BUD-Particle MSCs ability to suppress PBMC prolifera-
tion (Fig. 7F,G) and IFN-c secretion (Fig. 7H) compared to co-cul-
tures with unactivated MSCs.
Next we sought to examine the mechanism responsible for the
enhanced suppression. Soluble budesonide released from the MSCs
did not appear to be responsible, as PBMCs treated with 1 mM and
10 mM budesonide (no MSCs) were activated to the same degree as
untreated PBMCs (Fig. 8A). In order to determine if the enhanced
suppressive effect of BUD-Particle modified MSCs can be attributed
to IDO or that of other soluble factors, we used a widely used inhib-
itor of IDO, 1-methyl-DL-tryptophan (1-MT) to inhibit IDO activ-
ity. MSC:PBMC co-cultures were repeated at a MSC:PBMC ratio of
158 with or without the addition of 1 mM 1-MT. Inhibition of IDO
with 1-MT completely abolished BUD-Particle MSCs inhibitory
effect suggesting IDO is responsible for the enhanced immunomo-
dulatory potency of BUD-Particle MSCs (Fig. 8B).
Discussion
Herein we have demonstrated MSC immunomodulatory perform-
ance can be enhanced through intracellular delivery of steroids.
Budesonide treatment resulted in an over 4-fold increase in IFN-c
stimulated MSC IDO activity. Furthermore, budesonide treatment
enhanced the expression of IDO in MSCs from multiple donors and
restored IDO expression in over-passaged MSCs providing a tool to
address donor-donor and passage-passage variability in MSC
potency. The enhancement of MSC IDO expression was not limited
to budesonide, as similar levels of enhancement were also observed
with dexamethasone treatment. Unlike other cell types such as fibro-
blasts29 and lymphocytes41, MSC viability, metabolic activity, and
morphology, were not significantly impacted by exposure to a wide
range of budesonide concentrations. In addition to enhancement of
Figure 6 | Budesonide particles enhance MSC immunomodulatory potential. (A) Timing of MSC particle modification and exposure to IFN-c.
MSCs were modified with particles overnight, harvested and split into new flasks and then exposed to IFN-c for 48 hours. (B) Western blot of IDO
protein content measured from unmodified, Blank-Particle modified, or BUD-Particle modified MSCs exposed to 100 ng/ml IFN-c. b-actin shown as
loading control. (C) IDO content following 48 hours of IFN-c stimulation in untreated, budesonide preconditioned, and budesonide-particle modified
MSCs. b-actin shown as loading control. (D) Impact of BUD-Particle modification on MSC IDO activity with and without stimulation with 100 ng/ml
IFN-c. IDO activity measured by the production of L-kynurenine from generated fromMSC lysate incubated with tryptophan. 5 mg/ml rhIDOwas used
as an internal control for the assay(right axis). (Bars are mean 6 SEM, One-way ANOVA with Tukey correction for multiple comparisons, n 5 3,
*p , 0.001). (E) Bud-particle engineered MSCs exhibit enhanced suppression over budesonide preconditioned MSCs. Quantification of MSC
suppression of PBMCs after 5 day MSC:PBMC co-cultures. Data represents average of three experiments conducted with independent PBMC donors.
Un-stimulated control for each donor used to set threshold for PBMC activation. (Bars are mean 6 SEM, Ordinary One-way ANOVA with Tukey
correction for multiple comparisons, n 5 3, *p , 0.05).
www.nature.com/scientificreports
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Figure 7 | Engineered MSCs exhibit enhanced immunomodulatory potency. Gating and representative flow cytometry plot of (A) unstimulated
and (B) CD31/CD281 Dynabead stimulated CFSE stained PBMCs (CFSE vs. Forward Scatter). (C) Representative CFSE vs forward scatter flow
cytometry plots of PBMCs harvested from 5 day MSC:PBMC co-cultures. MSC:PBMC ratio and type of MSC particle modification are listed on each
column and row respectively. As PBMCs are activated and divide, CFSE is diluted 152, resulting in discrete daughter generations that shift to the left with
each cell division. (D) Quantification of MSC suppression of PBMCs harvested from three independent donors. Un-stimulated control for each donor
used to set threshold for PBMC activation. (E) IFN-c concentration measured from supernatant of MSC:PBMC co-cultures as marker of PBMC
activation. (F) Representative CFSE vs. forward scatter flow cytometry plots of PBMCs harvested from 5 day MSC:PBMC co-cultures containing MSCs
preconditioned with IFN-c to stimulate IDO activity. MSC:PBMC ratio and type of MSC particle modification are listed on each column and row
respectively. (G) Quantification ofMSC suppression of PBMCs harvested from three independent donors. Un-stimulated control for each donor used to
set threshold for PBMC activation. (H) IFN-c concentration measured from supernatant of preconditioned MSC:PBMC co-cultures as a marker of
PBMC activation. Un-stimulated PBMC controls showed no detectable secretion of IFN-c. (Bars are mean 6 SEM, Two-way ANOVA with Tukey
correction for multiple comparisons, n 5 3, *p , 0.05).
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MSC IDO activity, we also observed a reduction in MSC expression
of HLA-ABC at all doses in unstimulated conditions and a reduction
inHLA-DR expression at high doses in IFN-c stimulated conditions.
The reduced expression of MHCmolecules due to budesonide treat-
ment further minimizes the hypo-immunogenic phenotype of native
MSC. However, following IFN-c stimulation the level of HLA-ABC
and HLA-DR expression in budesonide treated MSC remains high,
and is thus unlikely to significantly alter MSC rejection in allogeneic
transplant settings. In fact, previous attempts to shield MSCs from
allo-rejection through reduction of HLA-ABC expression required
near complete blockade of HLA-ABC presentation in both unstimu-
lated and IFN-c stimulated conditions by viral immunoevasins42,43.
Nevertheless, approaches like this that reduce expression of MHC
molecules should be explored further to reduce immunological
events following allogeneic transplantation of MSC. Overall, bude-
sonide treatment maintained MSCs proliferative capabilities while
reducing MSC’s immunophenotype and greatly enhancing MSC’s
immunomodulatory potency through increased IDO activity. To
our knowledge, this is the first report of small molecule enhancement
of IDO activity in MSCs and the approach represents a significant
opportunity to augment MSC-based therapies.
Enhanced expression of IDO was shown to be dependent on both
the glucocorticoid receptor and FOXO3, as inhibition of either abro-
gated the effect. In addition to the current report of FOXO3 enhance-
ment of MSC immunosuppression, enhanced FOXO3 expression
has also recently been reported to be a marker of tolerogenic dend-
ritic cells44,45. FOXO3 expressing dendritic cells produce reduced
levels of IL-644 and elevated levels of IDO45. Inhibition of FOXO3
in tumor associated dendritic cells results in decreased levels of IDO
and enhanced anti-tumor immune responses45,46.While these studies
have examined the FOXO3-IDO pathway in the context of patho-
logy, we believe there is great potential to leverage the tolerogenic
effects to treat graft versus host disease, autoimmune conditions such
as Crohn’s and multiple sclerosis, and prevent rejection of trans-
planted tissues.
As the enhanced immunosuppressive phenotype of MSCs was
most prominent in cultures continuously exposed to budesonide
(Fig 3E,F), we employed an engineering strategy to establish pro-
longed control of MSCs. MSCs were engineered with budesonide
loaded PLGA particles that continuously release budesonide, result-
ing in a 5-fold enhancement in IFN-c stimulated MSC IDO activity.
BUD-Particle MSCs were shown to exhibit enhanced immunosup-
pressive potency in PBMC co-culture assays in an IDO dependent
manor. Inhibition of IDO with 1-MT led to abrogation of MSCs’
suppressive potential, implicating IDO as a primary mechanism of
budesonide mediated MSC enhancement. BUD-Particle engineered
MSCs were twice as potent in suppressing PBMC proliferation and
IFN-c secretion, as determined from ratiometric co-culture experi-
ments. Furthermore, pre-activating MSCs with IFN-c prior to the
co-culture further enhanced their potency. A pre-activation
approach could be attractive to maximize the systemic immunomo-
dulatory effects of MSCs, where cells may not come in contact with
sufficient levels of IFN-c to exert their activated systemic effects. In
contrast, for local administration ofMSCs, pre-activation is likely not
necessary as the MSCs will be activated in situ at the site of inflam-
mation. Enhancing the potency of a single MSC enables fewer MSCs
to be administered to achieve the same therapeutic effect and enables
a single cell to exert a significant impact on its microenvironment.
Using the particle–in-cell platform also enables local control of MSC
phenotype without requiring soluble glucocorticoid steroids, which
in vivo, can contribute to systemic side effects. In addition, this
technique can be used to augment the potency of MSCs harvested
from different donors and tissues, eliminating the need to select
MSCs from only donors or tissues that have high native immuno-
suppressive potential. Furthermore, as enhanced IDO activity has
been shown to lead to tolerance in the setting of pregnancy18, solid
organ transplantation47, and tumor evasion19, BUD-PLGA MSCs
may be able to extend their therapeutic window by promoting tol-
erance and evading immune clearance.
In the current study we have demonstrated the utility of BUD-
Particle MSCs in in vitro co-cultures. However, the potential benefits
of an MSC therapeutic with enhanced IDO expression could be far
reaching. This strategy may be used to augment therapeutic potency
of MSC therapies by suppressing active inflammation and inducing
tolerance in the setting of GvHD, Crohn’s disease, and transplant
biology. In addition, modified MSCs with enhanced IDO activity
could also be applied to prevent bio-fouling of orthopedic implants
and other medical devices due to IDO’s antimicrobial properties16.
Adaptation of this platform to other cell types to enhance IDO
expression (or other immunemodulators) for exogenous cell therapy
should be possible.We believe steroid preconditioning and especially
intracellular engineering strategies present an opportunity to control
the therapeutic potency of MSCs and expand the pool of potent cells
that can be used for therapies. This may be useful to reduce the
number of cells needed for each patient, and ultimately could lead
to improved patient outcomes.
Methods
Culture of MSCs. Primary human MSCs were obtained from Texas A&M Health
Science Center, College of Medicine, Institute for Regenerative Medicine at Scott &
White Hospital which has a grant from NCRR of the NIH, Grant #P40RR017447
Figure 8 | PBMC suppression is due to IDO and not soluble budesonide. (A) Budesonide alone does not suppress CD3/CD28 stimulated activation of
PBMCs. Quantification of budesonide mediated suppression or PBMC harvested from three independent donors. Un-stimulated control for each
donor used to set threshold for PBMC activation. (Bars aremean6 SEM) (B) Inhibition of IDO abolishesMSC suppression of PBMCs. Quantification of
MSC suppression of PBMCs harvested from three independent donors with and without addition of the IDO inhibitor 1-MT. Co-cultures performed
with MSCs preconditioned with IFN-c to stimulate IDO activity at an MSC:PBMC ratio of 158. Un-stimulated control for each donor used to set
threshold for PBMC activation. (Bars are mean 6 SEM, Two-way ANOVA with Tukey correction for multiple comparisons, n 5 3, *p , 0.05).
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(Donors 7076, 7081, and 7083, informed consent gathered prior to cell collection).
MSCs were maintained in cell-start (Invitrogen) coated flasks with StemPro MSC
SFM culture media (Invitrogen) supplemented with 1% (v/v) L-Glutamine
(Invitrogen), and 1% penicillin:streptomycin (Invitrogen). Cells were plated at a
density of 6,000 cells/cm2 and were passaged when flasks reached 70–80%
confluence. All experiments were performed with passage 3–6 MSCs (Population
doubling level between 4–8 from initial plating) unless indicated otherwise.
Metabolic activity, viability, and morphology assays. Metabolic activity of MSCs
was assessed by XTT (ATCC) following 24, 48, or 72 hour exposure to budesonide.
Briefly, 15,000 MSCs were plated in each well of a 96 well plate in 100 ml of culture
media containing DMSO vehicle and 0.001, 0.01, 0.1, 1, 10, or 100 mM budesonide.
Cultures were maintained for 24, 48, or 72 hours in a humidified culture chamber.
Culture media with no cells and wells with half the starting cell density were used as
internal controls for each experiment. All conditions were explored in 5 wells for each
experiment. To measure metabolic activity, 50 ml of activated XTT reagent was
prepared and added to each well per manufacturer’s instructions. The plate was
incubated for 3 hours and read at 450 nm and 630 nm for reference. To determine
the morphology and viability of budesonide treated MSCs, 30,000 cells were plated
into each well of a 24 well plate with vehicle or 0.001–100 mM budesonide
supplemented culturemedia. Cells were grown for 24, 48, or 72 hours. Before harvest,
4 random fields of each well were imaged at 103 using an inverted phase contrast
microscope to capture cell morphology and differences in cell proliferation. To
determine viability, cells were then harvested with Accutase, washed, and re-
suspended in 100 ml stain solution containing 5 ml/ml FITC-Annexin-V and 1 ml
propidium iodide (Invitrogen) and stained on ice for 15 min. Cells were washed with
400 ml PBS, centrifuged, re-suspended in fresh PBS and analyzed by an Accuri C6
flow cytometer. MSCs treated with staurosporine to induce cell death were used as a
positive control for each experiment. TUNEL staining of budesonide treated and
particle modified MSCs was performed per manufacture’s instructions using a in situ
cell death detection kit-fluorescein (Roche) to label double strand DNA breaks
indicative of apoptosis and counterstaining nuclei with Hoescht (Invitrogen). Fixed,
DNase treated MSCs (300 U/ml DNase, 1 mg/ml BSA, in 50 mM TrisHCL for
10 min at room temperature) were used as a positive control for double strand DNA
breaks. ImageJ (NIH) was used to quantify the number of dual stained nuclei, all
conditions were performed in triplicate.
Flow Cytometry. Expression of MHC molecules on MSCs following 24 hour
preconditioning or continuous exposure to various doses of budesonide was
determined using an Accuri C6 flow cytometer. For each condition, MSCs were
grown in T25 flasks, harvested with Accutase, washed, and split for staining with
either Alexa Fluor 488 anti-human HLA-ABC and Alexa Fluor 647 anti-human
HLA-DR or isotype controls. Cells were re-suspended in antibody solution in PBS 1
1% BSA and stained on ice for 15 min. Cells were washed with 400 ml PBS 1 1%BSA,
centrifuged, and analyzed by flow cytometry. Mean fluorescence intensity (MFI) was
determined using CFlow software.
IDOActivity Assay.MSC cultures were grown to 80% confluence in T75 flasks. Cells
were washedwith PBS, harvested withAccutase cell dissociation reagent (Invitrogen),
centrifuged, counted, and resuspended in 300 ml of ice cold PBS(without Ca21/Mg21
ions) with 0.1% (w/v) Triton X-100. Cell suspensions were lysed through triplicate
freeze thaw cycles, and briefly pulse sonicated using a probe sonicator with power
output of 3 W. Lysates were centrifuged at 25000 rcf at 4uC for 30 minutes. 250 ul of
sample supernatant, recombinant human IDO (rhIDO), or L-kynurenine standard
were mixed in a 151 ratio with 250 ml of IDO buffer (40 mM ascorbic acid, 20 mM
methylene blue, 200 mg/ml catalase, 800 mM L-tryptophan, in 50 mM MES buffer,
pH 6.5). Samples were incubated at 37uC for 45 min, followed by addition of 100 ml of
tricholoracetic acid (30%, w/v) and incubated at 52uC for 30 min. Samples were
centrifuged at 2500 rcf for 10 min to remove proteins, and 100 ml of the
resultant supernatant for each sample was added to a 96 well plate (all samples
and standards measured in duplicate). 100 ml of Ehrlich’s reagent (0.8% p-
dimethylaminobenzaldehyde in glacial acetic acid) was added to each well to induce a
color change. Samples were incubated at room temperature for 10 min and then read
on a microplate reader at 490 nm. rhIDO was used as a positive control in each assay
and an internal L-kynurenine standard (8–5000 mM) was included to determine
kynurenine production of IDO from MSC lysate.
siRNA Transfection. T25 flasks were seeded with 166,000 MSCs and incubated
overnight at 37u C. siRNA transfection was performed as follows. 10 ul of
Lipofectamine RNAiMAX transfection reagent (Invitrogen) per sample was diluted
into 0.5 ml of Opti-MEM media (Invitrogen), and gently mixed. 20 ml of
SignalSilence FOXO3 siRNA (Cell Signaling Technology, #6302S) or scramble
control siRNA (Cell Signaling Technology, #6201S) per sample was diluted into
0.5 ml of Opti-MEMmedia and gently mixed. Both solutions were incubated at room
temperature for five minutes. The solutions were then gently mixed and incubated for
twenty minutes at room temperature in the dark. During this time, the cells were
washed with PBS-/-. Following incubation, the PBS was removed, and 1 ml of siRNA
complex was added to each flask. The media of each flask was brought to 1.5 ml by
adding 0.5 ml OPTIMEMmedia and the cells were incubated at 37uC in the dark for
5 hours after which the media was replaced with full media.
Western Blots. MSC cell lysates were prepared by washing T25 plates with ice cold
PBS three times to remove media followed by addition of 200 ml ice cold RIPA buffer
(10 ml/ml PMSF solution, 10 ml/ml sodium orthovanadate, and 10 ml/ml protease
inhibitor cocktail). Cells were lifted using a cell scraper, collected in Eppendorf tubes,
and incubated on ice for 5 min. Lysate was then clarified by centrifugation at 8000 rcf
at 4uC for 10 min. The supernatant containing soluble protein was transferred to
clean tubes and total protein concentration was determined by microBCA (Thermo
Scientific). Western blots were performed using BioRad’s Mini Protean Tetra Cell
apparatus for the electrophoresis and transfer. Briefly, 10–20 mg of protein, mixed
151 with Laemmli Buffer were loaded into each well of 10% Tris-HCl gels with Tris
running buffer for SDS-PAGE. Proteins were then transferred to a Polyvinyl
difluoride membrane using the transfer apparatus according to the BioRad protocol.
Following transfer, the membrane was incubated with 5% BSA in TBST buffer
overnight, washed with TBST and incubated with primary antibodies (rabbit anti-
IDO (12006S), rabbit anti-stat-1 (9172P), rabbit anti-pstat-1 (7649P), rabbit anti-
FOXO3 (2497P), rabbit anti-b-actin (4970S), Cell Signaling). Horseradish peroxidase
conjugated anti-rabbit antibody (Cell Signaling, 7074S) was used as a secondary and
protein bands were visualized following incubation with Amersham ECL Prime
Detection Reagent (GE Healthcare) according to the manufacturer’s instructions.
Beta actin staining was performed to determine relative protein expressions and a
Precision Plus Protein Dual Color Standard (Bio-Rad) was used to determine the
molecular weight of the bands. Western blot images were analyzed and processed
using ImageJ (NIH).
Budesonide Particle Formulation. PLGA particles were formulated using an oil-in-
water single emulsion technique. 10 kDa molecular weight 50550 poly(lactic-co-
glycolic acid) with a carboxylic acid end group (inherent viscosity 0.15–0.25 dL/g)
was obtained fromLactel Absorbable polymers. 50 mg of PLGA, 8 mg of budesonide,
and 10 ml of DiI, were dissolved in 2 ml of dichloromethane in a glass vial. After
dissolving, PLGA:Drug solution was probe sonicated for 30 seconds to thoroughly
mix the drug within the polymer. The solution was then added drop wise to 20 ml of
filtered 1% (w/v) polyvinyl alcohol (80% hydrolyzed, Sigma) on ice while
homogenizing at 33,000 rpm using a Tissue Master 125 homogenizer (Omni
International). After 2 min homogenization, particles suspensionswere gently stirred
in a chemical hood for 4 hours to allow for evaporation of solvent. Suspensions were
then centrifuged, and washed with distilled water 3 times before lyopholization and
characterization. Blank particles were formed in parallel by omitting the addition of
budesonide in the above procedure. The zeta-potential of particles was modified
through adsorption of poly-l-lysine (PLL). Briefly, 6 mg/ml particle suspensions were
prepared in 100 mg/ml PLL solution in distilled water and gently agitated for 2 hours.
Particles were then frozen for subsequent use. The hydrodynamic diameter,
polydispersity, and zeta potential of particles was measured in distilled water using a
Malvern Zetaziser ZS90. Averages from three separate samples are reported. In
addition, 403 fluorescence microscopy images were acquired to confirm the size and
polydispersity of the particle suspensions.
Budesonide Particle Loading and Release Kinetics. High pressure liquid
chromatography (HPLC) was used to determine the drug loading, encapsulation
efficiency, and release kinetics of the budesonide microparticles. To determine drug
loading, 2–3 mg of particles were weighed into Eppendorf tubes, quickly spun into a
pellet, and swollen by addition of 500 ml methanol. Samples were agitated at 37uC for
2 hours to allow for complete release of budesonide from the particles. Samples were
centrifuged to pellet PLGA, and supernatant was collected, filtered, and analyzed by
an Agilent 1100 series HPLC. An Agilent Zorbax Eclipse XDB-C18 column (4 3
250 mm, 5 mm) was used with a mobile phase composed of 70530 acetonitrile:0.1%
acetic acid, 25 ml injection volume, and 1 ml/min flow rate. Budesonide was detected
by peak absorbance at 248 nm and quantified by comparison to internal standard
curves.
Drug loading was calculated as the dry mass of drug per mg of PLGA particles.
Encapsulation efficiency was calculated as the ratio of encapsulated drug to total drug
added to formulate particles. All samples were prepared in triplicate. Release kinetics
were determined by suspending 2 mg of particles in 200 ml of PBS placed in a 2 inch
section of 6–8,000 molecular weight cut off dialysis bag (Spectra Labs). Dialysis bags
were submerged in 40 ml of PBS to simulate infinite sync conditions and agitated at
37uC. At each time point, 1 ml of PBS was collected and replaced with fresh PBS.
Samples were frozen until HPLC analysis using the method as described above. All
samples were prepared in triplicate.
Particle Modification of MSCs. MSC particle modification was performed as
previously described38. Briefly, MSCs were cultured to 80% confluence prior to
particle modification. PLL coated budesonide or blank particles were thawed, briefly
sonicated to break up particle clumps, and suspended in 1% supplement StemPro
culture media to make 10 ml of 0.1 mg/ml particle media for each T75 flask. Flasks
were modified at the end of the day and incubated with particle media overnight.
Following particle modification, MSCs were washed three times with PBS, provided
with fresh full supplement culture media and allowed to rest for 24 hours before
subsequent experimentation. To confirm particle internalization, confocal
microscopy was performed as previously described39.
PBMC Isolation from whole blood. Fresh whole blood from 3 donors was collected,
after informed consent was obtained, from Research Blood Components for each
experiment (Watertown, MA). Upon delivery, blood was diluted 151 with sterile
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PBS-/- supplemented with 2% fetal bovine serum, layered on top of Ficoll-Paque
Premium (GE Healthcare), and centrifuged at 400 rcf for 30 min with the brake off.
The buffy coat was collected and washed with PBS:FBS solution. PBMCs were
counted and either used immediately or frozen in freezing media (RPMI
supplemented with 10% DMSO, 40% FBS, 1% Penicillin/Streptomycin, 1% L-Glut).
MSC:PBMC Co-cultures. The ratio of MSCs to PBMCs was established by adding
260,000 PBMCs and 65,000, 32,500, or 16,250 MSCs to each well of a 24-well plate.
MSCs were particle modified and allowed to rest a day before the co-culture
experiments. Unmodified, blank-particle modified, or bud-particle modified MSCs
were plated in 24 well plates and allowed to adhere. PBMCs labeled with a CellTrace
CFSE Cell Proliferation Kit (Invitrogen) according to the manufacturer’s
instructions. 260,000 PBMCs were then added to each well. To stimulate PBMCs
proliferation, 260,000 CD31/CD281 Dynabeads (StemCell Technologies) were also
added to each well. Total culture volume of each well was standardized to 0.5 ml of
RPMI supplemented with 10% FBS, 1% (v/v) L-Glutamine 1%
penicillin:streptomycin. PBMCs stimulated with Dynabeads but without MSCs were
used as an activated control and un-stimulated PBMCs grown without MSCs were
used as an un-activated control for each donor (Fig 7A,B). Co-cultures were
maintained for 5 days after which the media from the wells (containing PBMCs) was
collected and centrifuged to pellet the PBMCs. The conditioned media was then
collected for subsequent analysis. PBMC pellets were re-suspended in PBS-/-
containing 1% FBS and PBMC proliferation was assessed by flow cytometery. Un-
stimulated PBMC controls were used to set the threshold for PBMC activation for
each donor. To inhibit IDO activity, the MSC:PBMC co-cultures were repeated with
or without the addition 1 mM of the enzymatic inhibitor 1-methyl-DL-tryptophan
(1-MT, Sigma) prepared in RPMI media. Data was analyzed using Accuri’s CFlow
software. IFN-c content of co-culture supernatant was determined using an ELISA
MAX Deluxe Human IFN-c kit (Biolegend) by comparing to internal standards
according to manufacturer’s instructions.
Statistical Analysis. All statistics were performed using Prism 6 (GraphPad). Two-
wayANOVA’swere performed on data sets with two independent variables (dose and
time orMSC group andMSC:PBMC ratios) and one-way ANOVAwas performed on
data sets with a single independent variable (effect of budesonide conditioning on
MSC IDO activity). Fisher’s LSD test without correction for multiple comparisons
was used when assessing effect of budesonide doses on MSC metabolic activity and
viability as the test has a higher Type I error and would therefore highlight any
potential negative impact of budesonide on MSCs that would require further
evaluation. Bonferroni correction for multiple comparisons, which is a more
conservative test than the Fisher’s LSD method, was used for the MHC expression
data as all comparisons were made with respect to the untreated control. For all other
statistics, the mean of all groups were compared to all other groups and thus, Tukey
correction for multiple comparisons was used to minimize Type I error.
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